New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 31, 2012
08:26 EDTOMEROmeros shares oversold, secondary endpoint met, says Maxim
Maxim says that while OMS103HP missed its primary endpoint, the drug met its secondary endpoint of pain. The firm adds that pain is directly related to inflammation and the surgical process itself. Maxim finds Omeros shares oversold and said itís a buyer of the stock.
News For OMER From The Last 14 Days
Check below for free stories on OMER the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for OMER

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use